Efficacy and Safety Study of SHP647 as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)



Status:Recruiting
Conditions:Gastrointestinal, Crohns Disease
Therapuetic Areas:Gastroenterology
Healthy:No
Age Range:16 - 80
Updated:4/6/2019
Start Date:February 6, 2019
End Date:August 26, 2022
Contact:Shire Contact
Email:ClinicalTransparency@shire.com
Phone:+1 866 842 5335

Use our guide to learn which trials are right for you!

A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)

The purpose of this study is to evaluate the efficacy and safety of SHP647 as maintenance
treatment in participants with moderate to severe Crohn's disease (CD).


Inclusion Criteria:

- Participants and/or their parent or legally authorized representative (LAR) must have
an understanding, ability, and willingness to fully comply with study procedures and
restrictions.

- Participants must be able to voluntarily provide written, signed, and dated
(personally or via a LAR) informed consent and/or assent, as applicable, to
participate in the study.

- Participants must have completed the 16-week induction treatment period from study
SHP647-305 (NCT03559517) or SHP647-306 (NCT03566823) and met the following criteria at
baseline in maintenance study SHP647-307:

a) Meet endoscopic response criteria of a reduction in SES-CD from induction studies
SHP647-305 (NCT03559517) or SHP647-306 (NCT03566823) baseline by greater than or equal
to >=25% at Week 16 of induction studies SHP647-305 (NCT03559517) or SHP647-306
(NCT03566823) or b) Meet at least 1 of the following 4 criteria at baseline in
maintenance study SHP647-307, in addition to no worsening of endoscopic score as
measured by SES-CD relative to induction studies SHP647-305 (NCT03559517) or
SHP647-306 (NCT03566823) baseline: i) Achieving clinical remission as determined by
meeting the criteria for clinical remission using the 2-item PRO, that is, 2-item PRO
subscores of average worst daily abdominal pain <=3 (based on 11-point NRS) over the 7
most recent days* and average daily stool type frequency <=2 of type 6/7 (very soft
stools/liquid stools) as shown in the BSFS over the 7 most recent days*.

ii) A decrease of at least 100 points in CDAI score (CDAI-100) from induction studies
baseline.

iii) A decrease of >=30% and at least 2 points from induction studies baseline in the
average daily worst abdominal pain over the 7 most recent days*, with the average daily
stool frequency of type 6/7 (very soft stools/liquid stools) either: (i) not worsening from
induction studies baseline and/or (ii) meeting the criteria for clinical remission, that
is, 2-item PRO subscore of average daily stool frequency <=2 of type 6/7 (very soft
stools/liquid stools) as shown in the BSFS over the 7 most recent days*.

iv) A decrease of >=30% from induction studies SHP647-305 (NCT03559517) or SHP647-306
(NCT03566823) baseline in the average daily stool frequency of type 6/7 (very soft
stools/liquid stools) as shown in the BSFS over the 7 most recent days*, with the average
daily worst abdominal pain either: (i) not worsening from induction studies SHP647-305
(NCT03559517) or SHP647-306 (NCT03566823) baseline and/or (ii) meeting the criteria for
clinical remission, that is, 2-item PRO subscore of average worst daily abdominal pain <=3
(based on 11-point NRS) over the 7 most recent days*.

*Note: The 7 days may or may not be contiguous during the 10 days of data collection before
colonoscopy preparation, depending on days to be excluded because of missing data. If fewer
than 7 days are available, the criterion will be calculated on all available most recent 6
or 5 days. If fewer than 5 days are available, the criterion will be treated as missing.

- Participants receiving any treatments for CD are eligible provided they have been, and
are anticipated to be, on a stable dose for the designated period of time.

Exclusion Criteria:

- Participants who had major protocol deviations (as determined by the sponsor) in
induction studies SHP647-305 (NCT03559517) or SHP647-306 (NCT03566823).

- Participants who permanently discontinued investigational product because of an AE,
regardless of relatedness to investigational product, in induction studies SHP647-305
(NCT03559517) or SHP647-306 (NCT03566823).

- Participants who are likely to require surgery for CD during the study period, except
minor interventions (eg, seton placement for anal fistulas).

- Participants are females who became pregnant during induction studies SHP647-305
(NCT03559517) or SHP647-306 (NCT03566823), females who are planning to become pregnant
during the study period, or males or females of childbearing potential not agreeing to
continue acceptable contraception methods through the conclusion of study
participation.

- Participants who do not agree to postpone donation of any organ or tissue, including
male participants who are planning to bank or donate sperm, or female participants who
are planning to harvest or donate eggs, for the duration of the study and through 16
weeks after last dose of investigational product.

- Participants who, in the opinion of the investigator or the sponsor, will be
uncooperative or unable to comply with study procedures.

- Participants who have developed obstructive colonic stricture, or enterovesical or
enterovaginal fistulae during the induction study SHP647-305 (NCT03559517) or
SHP647-306 (NCT03566823).

- Participants who have a newly diagnosed malignancy or recurrence of malignancy (other
than resected cutaneous basal cell carcinoma, squamous cell carcinoma, or carcinoma in
situ of the uterine cervix that has been treated with no evidence of recurrence).

- Participants who have developed any major illness/condition or evidence of an unstable
clinical condition (example [eg,] renal, hepatic, hematologic, gastrointestinal
(except disease under study), endocrine, cardiovascular, pulmonary, immunologic [eg,
Felty's syndrome], or local active infection/infectious illness) that, in the
investigator's judgment, will substantially increase the risk to the participant if he
or she participates in the study.

- Participants with any other severe acute or chronic medical or psychiatric condition
or laboratory or ECG abnormality that may increase the risk associated with study
participation or investigational product administration or may interfere with the
interpretation of study results and, in the judgment of the investigator, would make
the participant inappropriate for entry into this study.

- Participants with known exposure to Mycobacterium tuberculosis (TB) since testing at
screening in induction studies SHP647-305 (NCT03559517) or SHP647-306 (NCT03566823)
and who have been advised to require treatment for latent or active disease but who
are without a generally accepted course of treatment.

- Participants with any of the following abnormalities in hematology and/or serum
chemistry profiles during the evaluation of the last visit in the induction studies
SHP647-305 (NCT03559517) or SHP647-306 (NCT03566823). If the results are considered by
the investigator to be transient and inconsistent with the participant's clinical
condition, may be repeated once prior to enrolment in Study SHP647-307.

1. Alanine aminotransferase and aspartate aminotransferase levels >= 3 × the upper
limit of normal (ULN).

2. Total bilirubin level >=1.5 × ULN or >2 × ULN if the participant has a known
documented history of Gilbert's syndrome.

3. Hemoglobin level <=80 gram per liter (g/L) (8.0 gram per deciliter [g/dL]).

4. Platelet count <=100 × 10^9/L (100,000 cells per cubic millimeter [mm^3]) or
>=1000 × 10^9/L (1,000,000 cells/mm^3).

5. White blood cell count <=3.5 × 10^9/L (3500 cells/mm^3).

6. Absolute neutrophil count<2 × 10^9/L (<2000 cells/mm^3)

7. Serum creatinine level >1.5 × ULN or estimated glomerular filtration rate <30
milliliter per minute (mL/min)/1.73 m^2 based on the abbreviated Modification of
Diet in Renal Disease Study Equation.

- Note: If platelet count is <150,000 cells/mm^3, a further evaluation should
be performed to rule out cirrhosis, unless another etiology has already been
identified.

- Participants who are investigational site staff members or relatives of those site
staff members or participants who are sponsor employees directly involved in the
conduct of the study.

- Participants who are participating in other investigational studies (other than
induction studies SHP647-305 [NCT03559517] or SHP647-306 [NCT03566823]) or plan to
participate in other investigational studies during this study.
We found this trial at
55
sites
Naples, Florida 34102
Principal Investigator: Raymond Phillips, MD
Phone: 239-649-1186
?
mi
from
Naples, FL
Click here to add this to my saved trials
8420 S. Eastern Ave.
Las Vegas, Nevada 89123
702-898-2088
Principal Investigator: Vrijendra Hoon, MD
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
823 SW Mulvane St
Topeka, Kansas 66606
785-368-0741
Principal Investigator: Curtis Baum, MD
Phone: 785-270-4856
?
mi
from
Topeka, KS
Click here to add this to my saved trials
500 S State St
Ann Arbor, Michigan 48109
(734) 764-1817
Principal Investigator: Peter Higgins, MD, MSc, PhD
Phone: 734-764-0507
University of Michigan The University of Michigan was founded in 1817 as one of the...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Atlanta, Georgia 30308
Principal Investigator: Bruce Salzberg, MD
Phone: 678-957-0057
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Brooklyn, New York 11215
Principal Investigator: Jorge Serje, MD
Phone: 718-499-6099
?
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Cape Coral, Florida 33991
Principal Investigator: Alfonso Garcia Bello, MD
Phone: 239-800-4893
?
mi
from
Cape Coral, FL
Click here to add this to my saved trials
Chesterfield, Michigan 48047
Principal Investigator: Ronald Fogel, MD
Phone: 586-598-3329
?
mi
from
Chesterfield, MI
Click here to add this to my saved trials
Cincinnati, Ohio 45219
Principal Investigator: Christopher South, MD
Phone: 513-751-6667
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Clearwater, Florida 33762
Principal Investigator: L Weiss, MD
Phone: 727-347-0536
?
mi
from
Clearwater, FL
Click here to add this to my saved trials
Colorado Springs, Colorado 80907
Principal Investigator: Bhaktasharan Patel, MD
Phone: 719-636-1201
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
2709 North Tejon Street
Colorado Springs, Colorado 80907
Principal Investigator: Daniel Soteres, MD
Phone: 719-473-0872
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Concord, New South Wales
Principal Investigator: Rupert Leong, MBBS, MD
Phone: +61297676111
?
mi
from
Concord,
Click here to add this to my saved trials
967 North University Drive
Coral Springs, Florida 33071
Principal Investigator: Vipin Gupta, BS, MB, MD
Phone: 954-428-2480
?
mi
from
Coral Springs, FL
Click here to add this to my saved trials
Corona, California 92879
Principal Investigator: M. Mazen Jamal, MD
Phone: 951-220-4029
?
mi
from
Corona, CA
Click here to add this to my saved trials
21212 Northwest Freeway
Cypress, Texas 77429
Principal Investigator: Ayub Hussain, MD
Phone: 281-477-9305
?
mi
from
Cypress, TX
Click here to add this to my saved trials
Decatur, Georgia 30033
Principal Investigator: David Rausher, MD
Phone: 404-296-1986
?
mi
from
Decatur, GA
Click here to add this to my saved trials
2925 Vernon Place
Fairfield, Ohio 45014
Principal Investigator: Jeffrey Stotz, MD
Phone: 513-860-4801
?
mi
from
Fairfield, OH
Click here to add this to my saved trials
103 Doctor's Place
Galax, Virginia 24333
Principal Investigator: Robert Benish, MD
Phone: 276-236-2947
?
mi
from
Galax, VA
Click here to add this to my saved trials
Germantown, Tennessee 38138
Principal Investigator: Ziad Younes, MD
Phone: 901-820-0090
?
mi
from
Germantown, TN
Click here to add this to my saved trials
20 Tower Court
Gurnee, Illinois 60031
Principal Investigator: Fred Rosenberg, MD
Phone: 847-604-8700
?
mi
from
Gurnee, IL
Click here to add this to my saved trials
200 Medical Center Drive
Hazard, Kentucky 41701
Principal Investigator: Uday Shankar, MD
Phone: 606-439-3952
?
mi
from
Hazard, KY
Click here to add this to my saved trials
Houma, Louisiana 70360
Principal Investigator: Nathaniel Winstead, MD
Phone: 985-601-2662
?
mi
from
Houma, LA
Click here to add this to my saved trials
19255 Park Row Drive
Houston, Texas 77084
Principal Investigator: Mouhamad Al-Sabbagh, MD
Phone: 281-768-5879
?
mi
from
Houston, TX
Click here to add this to my saved trials
Houston, Texas 77084
Principal Investigator: James Maher, MD
Phone: 281-945-4368
?
mi
from
Houston, TX
Click here to add this to my saved trials
Houston, Texas 77074
Principal Investigator: Dilawar Ajani, MD
Phone: 281-216-3658
?
mi
from
Houston, TX
Click here to add this to my saved trials
Kissimmee, Florida 34759
Principal Investigator: Syed Mumtaz, MBBS, MD
Phone: 407-964-1207
?
mi
from
Kissimmee, FL
Click here to add this to my saved trials
1 Lakeshore Drive
Lake Charles, Louisiana 70601
Principal Investigator: Ricardo McCall, MD
Phone: 337-493-5310
?
mi
from
Lake Charles, LA
Click here to add this to my saved trials
Lancaster, California 93534
Principal Investigator: Jatinder Pruthi, MD
Phone: 310-684-2494
?
mi
from
Lancaster, CA
Click here to add this to my saved trials
Little Rock, Arkansas 72209
Principal Investigator: Meenakshi Budhraja, MD
Phone: 501-492-9175
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
Mesa, Arizona 85206
Principal Investigator: Doo-Sang Cho, MD
Phone: 480-889-1211
?
mi
from
Mesa, AZ
Click here to add this to my saved trials
Miami, Florida 33176
Principal Investigator: Gil Fernandez-Yera
Phone: 305-702-1594
?
mi
from
Miami, FL
Click here to add this to my saved trials
Michigan City, Indiana 46360
Principal Investigator: Minesh Patel, MD
Phone: 219-879-0333
?
mi
from
Michigan City, IN
Click here to add this to my saved trials
Naples, Florida 34110
Principal Investigator: Steven Meckstroth, MD
Phone: 239-593-6201
?
mi
from
Naples, FL
Click here to add this to my saved trials
New Orleans, Louisiana 70115
Principal Investigator: Patrick Dennis, MD
Phone: 504-336-2667
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
310 Sterling Drive
Orchard Park, New York 14127
Principal Investigator: Albert Diaz-Ordaz, MD
Phone: 206-661-0073
?
mi
from
Orchard Park, NY
Click here to add this to my saved trials
Orlando, Florida 32804
Principal Investigator: Kwabena Ayesu, MD
Phone: 407-271-8030
?
mi
from
Orlando, FL
Click here to add this to my saved trials
Phoenix, Arizona 85018
Principal Investigator: Joseph Lillo, DO
Phone: 602-788-3437
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Pinellas Park, Florida 33781
Principal Investigator: Venkata Iyunni, MD
Phone: 727-347-8839
?
mi
from
Pinellas Park, FL
Click here to add this to my saved trials
Rialto, California 92377
Principal Investigator: Zeid Kayali, MBA, MD
Phone: 909-883-2999
?
mi
from
Rialto, CA
Click here to add this to my saved trials
Saint Augustine, Florida 32086
Principal Investigator: Anis Ahmadi, MD
Phone: 904-824-1776
?
mi
from
Saint Augustine, FL
Click here to add this to my saved trials
Saint Louis, Missouri 63110
Principal Investigator: George Christophi, MD
Phone: 314-273-1947
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Saint Paul, Minnesota 55114
Principal Investigator: Robert McCabe, Jr.
Phone: 612-870-5595
?
mi
from
Saint Paul, MN
Click here to add this to my saved trials
150 East Sonterra Boulevard
San Antonio, Texas 78229
Principal Investigator: Jeff Bullock, MD
Phone: 210-558-2794
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
San Pablo, California 94806
Principal Investigator: Mark Kogan, MD
Phone: 415-408-8734
?
mi
from
San Pablo, CA
Click here to add this to my saved trials
Shreveport, Louisiana 71103
Principal Investigator: Humberto Aguilar, MD
Phone: 318-525-3233
?
mi
from
Shreveport, LA
Click here to add this to my saved trials
State College, Pennsylvania 16803
Principal Investigator: Joel Haight, MD
Phone: 814-272-4445
?
mi
from
State College, PA
Click here to add this to my saved trials
Statesville, North Carolina 28677
Principal Investigator: Vivek Trivedi, MD
Phone: 704-873-4277
?
mi
from
Statesville, NC
Click here to add this to my saved trials
Tamarac, Florida 33321
Principal Investigator: Kevin Bender, MD
Phone: 954-537-2100
?
mi
from
Tamarac, FL
Click here to add this to my saved trials
1109 East Reelfoot Avenue
Union City, Tennessee 38261
Principal Investigator: Kofi Nuako, MD
Phone: 731-884-0600
?
mi
from
Union City, TN
Click here to add this to my saved trials
451 North Texas Avenue
Webster, Texas 77598
Principal Investigator: Advitya Malhotra, MD
Phone: 281-557-2527
?
mi
from
Webster, TX
Click here to add this to my saved trials
Winchester, Massachusetts 22601
Principal Investigator: Nicholas Snow, MD
Phone: 540-667-1244
?
mi
from
Winchester, MA
Click here to add this to my saved trials
Worcester, Massachusetts 01605
Principal Investigator: Jean Marie Houghton, MD
Phone: 774-442-4098
?
mi
from
Worcester, MA
Click here to add this to my saved trials
Wyoming, Michigan 49519
Principal Investigator: Allan Coates, DO
Phone: 616-608-8730
?
mi
from
Wyoming, MI
Click here to add this to my saved trials
Wyomissing, Pennsylvania 19610
Principal Investigator: Nirav Shah, MD
Phone: 610-374-4401
?
mi
from
Wyomissing, PA
Click here to add this to my saved trials